Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
How did IRWD's recent EPS compare to expectations?
The most recent EPS for Ironwood Pharmaceuticals Inc is $0.24, not beating expectations of $0.24.
How did Ironwood Pharmaceuticals Inc IRWD's revenue perform in the last quarter?
Ironwood Pharmaceuticals Inc revenue for the last quarter is $0.24
What is the revenue estimate for Ironwood Pharmaceuticals Inc?
According to 6 of Wall street analyst, the revenue estimate of Ironwood Pharmaceuticals Inc range from $139.76M to $112.01M
What's the earning quality score for Ironwood Pharmaceuticals Inc?
Ironwood Pharmaceuticals Inc has a earning quality score of A-/61.51707. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Ironwood Pharmaceuticals Inc report earnings?
Ironwood Pharmaceuticals Inc next earnings report is expected in 2026-08-05
What are Ironwood Pharmaceuticals Inc's expected earnings?
Ironwood Pharmaceuticals Inc expected earnings is $93.93M, according to wall-street analysts.
Did Ironwood Pharmaceuticals Inc beat earnings expectations?
Ironwood Pharmaceuticals Inc recent earnings of $106.5M does not beat expectations.
Beta
